atai Life Sciences (ATAI) — atai Life Sciences cut its Q2 2025 net loss to $27.7 million from $57.4 million a year earlier, while cash, equivalents and short-term securities rose to $95.9 million.
With an additional $50 million in committed funding announced in July, management said combined-company resources should fund operations into the second half of 2027 as it advances its planned strategic combination with Beckley Psytech, whose BPL-003 (intranasal 5-MeO-DMT) recently delivered positive Phase 2b treatment-resistant depression data.
Source: ir.atai.com
For the rest of that week's sector news, read our week in review.